SEC Form 4 · accession 0001209191-15-047616
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Mar 12, 2015
Accepted (ET)
May 28, 2015 · 5:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Mar 12, 2015 | G | 190 | $0.00 | D | 94,511 | I | See footnote |
| Common stockF4,F2 | May 27, 2015 | S | 8,929 | $120.05 | D | 85,582 | I | See footnote |
| Common stockF5 | holding | — | — | — | 238,772 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects a gift of shares from the reporting person to Brother Wolf Animal Rescue.
- F2Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
- F3This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $120.00 to $120.81. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.